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Abstract
Background: We recently developed a chelating platform based on the macrocycle
1,4,7-triazacyclononane with up to three, five-membered azaheterocyclic arms for the
development of 68Ga- and 64Cu-based radiopharmaceuticals. Here, a 68Ga-labelled
conjugate comprising the bifunctional chelator NODIA-Me in combination with the
αvß3-targeting peptide c(RGDfK) has been synthesized and characterized. The primary
aim was to evaluate further the potential of our NODIA-Me chelating system for the
development of 68Ga-labelled radiotracers.
Results: The BFC NODIA-Me was conjugated to c(RGDfK) by standard peptide
chemistry to obtain the final bioconjugate NODIA-Me-c(RGDfK) 3 in 72% yield.
Labelling with [68Ga]GaCl3 was accomplished in a fully automated, cGMP compliant
process to give [68Ga]3 in high radiochemical yield (98%) and moderate specific
activity (~ 8 MBq nmol− 1). Incorporation of the Ga-NODIA-Me chelate to
c(RGDfK) 2 had only minimal influence on the affinity to integrin αvß3 (IC50 values
[natGa]3 = 205.1 ± 1.4 nM, c(RGDfK) 2 = 159.5 ± 1.3 nM) as determined in
competitive cell binding experiments in U-87 MG cell line. In small-animal PET
imaging and ex vivo biodistribution studies, the radiotracer [68Ga]3 showed low
uptake in non-target organs and specific tumor uptake in U-87 MG tumors.
Conclusion: The results suggest that the bifunctional chelator NODIA-Me is an
interesting alternative to existing ligands for the development of 68Ga-labelled
radiopharmaceuticals.
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Background
The transmembrane integrin αvß3 receptor is a well-established target for imaging
tumor angiogenesis. The integrin αvß3 receptor is upregulated in activated endothelial
cells of tumors undergoing angiogenesis but is not expressed in normal cells and qui-
escent vessel cells making it a key target for the diagnosis of malignant tumors and
metastases (Hood and Cheresh 2002; Sheldrake and Patterson 2009). Besides applica-
tions in oncology, imaging of αvß3 expression is also applied in cardiology and inflam-
matory diseases (Kourtzelis et al. 2017; Mandic et al. 2016).
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In recent years, many peptide-based probes comprising of either one or multiple
αvß3-targeting vectors were developed for noninvasive imaging of αvß3 expression by
PET (positron emission tomography) (Gurrath et al. 1992). Reported compounds have
been labelled with a range of radionuclides including fluorine-18, gallium-68 and
copper-64 (Cai and Conti 2013; Chen et al. 2016; Haubner et al. 2014). For example,
the radiotracers [18F]Fluoro-Galacto-RGD (Haubner et al. 2004), [68Ga/64Cu]Ga/Cu-
NODAGA-RGD (Dumont et al. 2011), [68Ga/64Cu]Ga/Cu-DOTA-RGD (Dumont et al.
2011), [64Cu]Cu-AmBaSar-RGD (Cai et al. 2010) and [68Ga]Ga-TRAP-(RGD)3 (Notni
et al. 2013) have demonstrated promise for imaging αvß3. Several αvß3-targeting
radiotracers have been evaluated in clinical studies including [18F]Fluoro-Galacto-RGD,
[18F]Fluoro-RGD-K5, [18F]FPPRGD2, [18F]Fluoro-fluciclatide, [18F]Fluoro-alfatide,
[18F]Fluoro-alfatide II, [68Ga]Ga-NOTA-RGD and [68Ga]Ga-NOTA-PRGD2 (Cai and
Conti 2013; Chen et al. 2016; Haubner et al. 2014).
We recently developed a chelating platform based on the macrocycle 1,4,7-triazacy-
clononane (TACN) with additional five-membered azaheterocyclic arms for the coord-
ination of the PET radionuclides gallium-68 and copper-64 (Gotzmann et al. 2016;
Schmidtke et al. 2017). Initial work revealed that these chelators are characterized by
their excellent complexation properties for both radiometals. Labelling with copper-64
was achieved rapidly under very mild conditions (< 1 min incubation time, room
temperature) over a pH range of 4.0 to 8.0 to give products with high specific activities
(120–180 MBq nmol− 1). Stability studies also demonstrated that 64Cu-labelled
complexes have high kinetic stability in vitro (Gotzmann et al. 2016). In subsequent
work, we discovered that the imidazole-type ligands can also be labelled with gallium-
68 (Schmidtke et al. 2017). Complexation properties were comparable to the ligand
NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) (Schmidtke et al. 2017). More re-
cently, we described the bifunctional chelator (BFC) NODIA-Me (2-(4,7-bis((1-methyl-
1H-imidazol-2-yl)methyl)-1,4,7-triazonan-1-yl)acetic acid), in which one of the methyli-
midazole arms was replaced with an acetic acid group. This acetic acid group served as
site for the attachment of a prostate-specific membrane antigen targeting vector via
peptide bond formation (Schmidtke et al. 2017). In more recent small-animal imaging
and ex vivo biodistribution studies, 64Cu- and 68Ga-labelled PSMA-targeting conjugates
comprising the BFC NODIA-Me specifically delineated PSMA-positive LNCaP tumors
(Läppchen et al. 2018). Moreover, no significant decomplexation/transchelation of the
radiometal chelate was noted in vivo, underscoring the potential use of our chelating
platform for radiopharmaceutical applications.
In the present study, we sought to expand the scope of the BFC NODIA-Me
for the development of 68Ga-based radiopharmaceuticals. Here, we report studies
on a 68Ga-labelled αvß3-targeting probe conjugated to the BFC NODIA-Me. The
αvß3-targeting bioconjugate NODIA-Me-c(RGDfK) was evaluated in vitro by a
competitive cell binding assay, followed by small-animal PET imaging and ex vivo
biodistribution studies.
Methods
General
Chemicals and solvents were purchased from Sigma-Aldrich and TCI Europe, and used
as received. The bifunctional chelator NODIA-Me 1 was prepared as previously
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described (Schmidtke et al. 2017). The peptide c(RGDfK) 2 was purchased from ABX
(Radeberg, Germany). The radioligand [125I]I-echistatin was obtained from Perkin
Elmer (Boston, USA). Low resolution electrospray ionisation mass spectrometry (LR-
ESI(+)-MS) was performed on a PerkinElmer Flexar SQ 300 MS Detector.
Radiolabelling with [68Ga]GaCl3 was accomplished using a fully automated synthesis
module (Pharmtracer, Eckert & Ziegler, Berlin, Germany) with an IGG100 generator
(Eckert & Ziegler, Berlin, Germany). High performance liquid chromatography (HPLC)
was performed on an Agilent 1260 Infinity System equipped with an Agilent 1200
DAD UV detector (UV detection at 220 nm) and a Raytest Ramona radiation detector
(Raytest GmbH, Straubenhardt, Germany) in series. A Phenomenex Jupiter Proteo
(250 × 4.60 mm) column was used for analytical HPLC. The solvent system was A =
H2O (0.1% TFA) and B = acetonitrile (0.1% TFA). The gradient was 0–1 min 5% B, 1–
20 min 40% B at a flow rate of 1 mL min− 1. Semi-preparative HPLC was performed on
a Knauer Smartline 1000 HPLC system in combination with a Macherey Nagel VP
250/21 Nucleosil 120–5 C18 column. Semi-preparative HPLC gradient was 0–40 min
5–60% B at a flow rate of 12 mL min− 1. Samples were lyophilized using a Christ Alpha
1–2 LD plus lyophilizer. All instruments measuring radioactivity were calibrated and
maintained in accordance with previously reported routine quality-control procedures
(Zanzonico 2009). Radioactivity was measured using an Activimeter ISOMED 2010
(Nuklear-Medizintechnik, Dresden, Germany). For accurate quantification of radio-
activity, experimental samples were counted for 1 min on a calibrated Perkin Elmer
(Waltham, MA, USA) 2480 Automatic Wizard Gamma Counter by using a dynamic
energy window of 400–600 keV for gallium-68 (511 keV emission).
Synthesis of NODIA-Me-c(RGDfK) (3)
NODIA-Me 1 (1.25 mg, 0.003 mmol), HATU (1-[bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate) (2 mg, 0.005 mmol) and
DIPEA (N,N-diisopropylethylamine) (2.6 mg, 4 μL, 0.02 mmol) were mixed in 500 μL
anhydrous N,N-dimethylformamide (DMF) and allowed to stir for 30 min at room
temperature (r.t.). Next, the peptide c(RGDfK) 2 (2 mg, 0.003 mmol) in 100 μL DMF
was added and stirring was continued for additional 2 h. The solvent was removed by
rotary evaporation and the residue was taken up in water/acetonitrile (50:50 v/v) with
0.1% trifluoroacetic acid (TFA) and purified by semi-preparative HPLC. Fractions con-
taining the product were combined and lyophilized to give compound 3 as white pow-
der (2.3 mg, 0.0024 mmol, 72%). LR-ESI-MS calcd m/z for C45H69N16O8 ([M +H]
+):
961.5, found: 961.8. RP-HPLC (analytical): tR = 11:10 min. RP-HPLC (semi-preparative):
tR = 6:10 min.
Preparation of natGa-NODIA-Me-c(RGDfK) ([natGa]3)
The bioconjugate NODIA-Me-c(RGDfK) 3 (500 μg, 0.52 μmol) in 250 μL H2O was
mixed with 250 μL of metal stock solution containing 1.5 equivalents of Ga(NO3)3 and
heated at 95 °C for 15 min. After cooling to r.t., the complex was purified using C18
Sep-Pak cartridge, which was preconditioned with 5 mL each of EtOH and H2O, re-
spectively. After loading, the cartridge was washed with 2 mL H2O and the product
was eluted using 2 mL EtOH:H2O (50:50 v/v). After evaporation of EtOH at ambient
Läppchen et al. EJNMMI Radiopharmacy and Chemistry  (2018) 3:6 Page 3 of 11
temperature, the remaining solution was lyophilized to give [natGa]3 (470 μg, 0.
45 μmol, 88%). RP-HPLC (analytical): tR = 14:20 min. LR-ESI-MS calcd m/z for
C45H68GaN16O8 ([M]
2+): 514.5, found: 514.9.
Radiosynthesis of [68Ga]Ga-NODIA-Me-c(RGDfK) ([68Ga]3)
Radiolabelling of 3 with [68Ga]GaCl3 was accomplished by using the Modular-Lab
PharmTracer automated synthesis module (Eckert&Ziegler, Berlin, Germany) as previ-
ously described (Schmidtke et al. 2017). An amount of 20 μg of 3 was used per label-
ling. The generator eluate provided ~ 350–450 MBq [68Ga]GaCl3. The radiochemical
purity (RCP) was > 98% and the decay corrected radiochemical yield (RCY) was > 98%.
The mean molar activity was Am = 8.4 ± 2.1 MBq nmol
− 1 (n = 15). RP-HPLC (analytical,
radioactivity detector): tR ([
68Ga]3) = 14:30 min.
Lipophilicity (log Doct/PBS) measurements
For log Doct/PBS measurements, 1–2 MBq of [
68Ga]3 in 20 μL labelling buffer were
added to a mixture of phosphate buffered saline (PBS) pH 7.4 (Gibco Life Science
Technologies, 4 mM phosphate buffer, 0.15 M NaCl) (480 μL) and octanol (500 μL).
Samples were shaken for 30 min at room temperature, centrifuged at 13,200 rpm for
5 min and 100 μL of each phase were counted using a Packard Cobra gamma counter.
Experiments were performed in triplicate.
Cell culture
U-87 MG cells (ATCC, Manassas, VA, USA) were cultured at 37 °C in a 5% CO2 at-
mosphere (Dulbecco modified Eagle medium with GlutaMAX containing 10% fetal bo-
vine serum, 1% 10,000 U mL− 1 penicillin and 10,000 U mL− 1 streptomycin, 1%
sodium-pyruvate 100 mM).
Competitive binding assay
The binding affinity of [natGa]3 was determined by a cell-based competitive binding
assay in the human glioma cell line U-87 MG with [125I]I-echistatin as the radioligand
as previously described (Dumont et al. 2011). Binding assays were performed in 24-well
plates precoated with poly-L-lysine. Briefly, each compound at different concentrations
(0–10,000 nM) was incubated for 2 h at r.t. with [125I]I-echistatin (30.000 cpm well− 1)
and 2 × 105 U-87 MG cells well− 1. After incubation, cells were washed three times with
ice cold binding buffer and cell-associated activity recovered by addition of 1 M NaOH.
Radioactivity was measured by a gamma counter and data fitted using non-linear re-
gression (GraphPad Prism). Experiments were performed two times in triplicate.
Small-animal PET imaging
All animal experiments complied with the current laws of the Federal Republic of
Germany and were conducted according to German Animal welfare guidelines. Normal
female athymic Balb/c nude mice (17–20 g, 4–6 weeks old) were obtained from Janvier
SAS (St. Berthevin Cedex, France). Mice were provided with food and water ad libitum.
U-87 MG tumors were inoculated on the right shoulder by sub-cutaneous injection of
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5×106 cells in a 100 μL cell suspension of a 1:1 v/v mixture of media with reconstituted
basement membrane (GFR BD Matrigel™, Corning BV, Amsterdam, Holland).
For PET imaging studies, mice (n = 3) were injected with 100 μL sterile filtered phos-
phate buffered saline formulations pH 7.4 of [68Ga]3 (7–11 MBq) by intravenous tail-
vein injection and anesthetized with isoflurane (2–4% in air) 5–10 min prior image
acquisition. PET imaging was performed on a Focus 120 microPET scanner at 1 h after
administration. Data were acquired 1 h post administration in list mode. Reconstruc-
tion was performed using unweighted OSEM2D. Image analysis was performed using
AMIDE. Image counts per second per voxel (cps/voxel) were calibrated to activity con-
centrations (Bq mL− 1) by measuring a 3.5 cm cylinder phantom filled with a known
concentration of radioactivity. For data analysis, it was explicitly assumed that the
density of tissue equals 1.0 g cm− 3, hence the reported units of %IA g− 1 are identical
to %IA cm− 3. Specificity of [68Ga]3 was confirmed by competitive inhibition (blocking)
co-injecting the peptide c(RGDfK) 2 (5 mg kg− 1 = ~ 100 nmol mouse− 1; n = 3) in
approximately 100fold excess compared to the radiotracer.
Ex vivo biodistribution
For each compound, a total of five animals were injected with [68Ga]3 (7–11 MBq) in
100 μL sterile filtered phosphate buffered saline via a tail vein. At 1 h p.i., animals were
sacrificed by isoflurane anesthesia. Organs of interest were dissected, weighed and
assayed for radioactivity in a gamma counter. The percent injected activity per gram
(%IA g− 1) for each tissue was calculated by comparison of the tissue counts to a
standard sample prepared from the injectate. Specificity of [68Ga]3 was determined by
co-injection of the peptide c(RGDfK) 2 (5 mg kg− 1 = ~ 100 nmol mouse− 1).
Results and discussion
Bioconjugate synthesis
The bifunctional chelator NODIA-Me 1 bearing an acetic acid residue for the covalent
attachment of appropriate targeting vectors was successfully conjugated to the peptide
c(RGDfK) 2 in DMF using HATU as coupling reagent (Scheme 1). The final bioconju-
gate 3 was obtained in 72% yield after purification by semi-preparative RP-HPLC. The
identity and purity of compound 3 (> 98%) was determined by mass spectrometry and
analytical RP-HPLC.
Radiochemistry
Radiosynthesis of [68Ga]3 was performed using an automated synthesis module by
heating 20 μg of compound 3 with [68Ga]GaCl3(aq.) at 95 °C for 10 min as previously
described (Schmidtke et al. 2017). The RCP and the decay corrected RCY for [68Ga]3
were measured to > 98% with mean specific activities of ~ 8 MBq nmol− 1. The identity
of [68Ga]3 was confirmed by analytical HPLC using the non-radioactive reference
compound.
Lipophilicity
The radiolabelled conjugate [68Ga]3 is highly hydrophilic with a log Doct/PBS value of −
3.89 ± 0.02. Interestingly, in a series of c(RGDfK) based radiopharmaceuticals with
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different bifunctional chelators that give gallium complexes of different overall charge,
[68Ga]3 with a positively charged metal chelate was more hydrophilic than [68Ga]Ga-
NODAGA-c(RGDfK) or [68Ga]Ga-DOTA-c(RGDfK), which have a neutral and negative
overall charge on the metal chelate (log D values: − 3.27 ± 0.01 and − 2.86 ± 0.01),
respectively (Dumont et al. 2011).
Competitive binding assay
The binding affinity of [natGa]3 was compared to c(RGDfK) 2 in a competitive binding
assay on αvß3-positive U-87 MG cells using [
125I]I-echistatin as radioligand. Both
compounds inhibited the binding of [125I]I-echistatin in a dose dependent manner. The
IC50 values for 2 and [
natGa]3 were determined to IC50 = 159.5 ± 1.3 nM and IC50 = 205.1
± 1.4 nM, which are in accordance to previously reported IC50 values (Dumont et al.
2011). Introduction of the metal chelate had only a minimal effect on receptor binding
resulting in a slightly lower affinity of [natGa]3 compared to peptide 2. Corresponding
inhibition curves are given in Fig. 1.
In vivo studies
In our efforts to demonstrate the applicability of our novel chelating system for radio-
pharmaceutical applications, we assessed the stability and pharmacokinetic profile of
[68Ga]3 by small-animal experiments.
Ex vivo biodistribution
Biodistribution data for [68Ga]3 are presented in Table 1. For comparison, equivalent data
taken from the literature are also given for compounds [68Ga]Ga-NODAGA-c(RGDfK)
and [68Ga]Ga-DOTA-c(RGDfK) (Dumont et al. 2011). The primary difference between
these three compounds is the change in chelator. The highest activity accumulation of
[68Ga]3 among all tissues at 1 h p.i. was seen for the αvß3-positive U-87 MG tumors with
2.10 ± 0.09 %IA g− 1. Despite differences in the tumor models used, accumulation of
[68Ga]3 in U-87 MG xenografts is comparable to that of previously reported 68Ga-labelled
RGD peptides in αvß3-expressing tumors (Boros et al. 2012; Ferreira et al. 2012; Pohle et
al. 2012). In comparison to [68Ga]Ga-NODAGA-c(RGDfK) and [68Ga]Ga-DOTA-
c(RGDfK), which have previously been evaluated under similar conditions, tumor uptake
of [68Ga]3 was somewhat lower than that of [68Ga]Ga-NODAGA-c(RGDfK) and
[68Ga]Ga-DOTA-c(RGDfK) (Table 1) (Dumont et al. 2011). Tumor uptake was
Scheme 1 Synthesis of NODIA-Me-c(RGDfK) 3. HATU, DIPEA, DMF, r.t., 72%
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significantly reduced by 86% (P value < 0.0001) by co-injection of c(RGDfK), indicating re-
ceptor specific binding in tumor tissue. Accumulation in the kidneys and the liver was
low considering the positively charged NODIA-Me metal chelate because positively
charged compounds might be retained in both organs (Dearling et al. 2013; Dearling et al.
2015; Sprague et al. 2007). In previous animal studies of our 64Cu-labelled chelators
(without a targeting vector), substantial uptake and retention of activity was observed in
the kidneys by small-animal PET imaging (Gotzmann et al. 2016). This kidney
Table 1 Ex vivo biodistribution of [68Ga]3 in mice bearing αvß3-positive U-87 MG tumors at 1 h p.i.
along with blocking studies in comparison to [68Ga]Ga-NODAGA-c(RGDfK) and [68Ga]Ga-DOTA-
c(RGDfK) (data taken from ref. Dumont et al. 2011). Data are expressed as %IA g− 1 and represent
mean ± SD (n = 5)
Organ [68Ga]3 [68Ga]Ga-NODAGA-c(RGDfK) [68Ga]Ga-DOTA-c(RGDfK)
1 h 1 h blockade 1 h 1 h
Blood 0.54 ± 0.08 0.50 ± 0.03 0.16 ± 0.03 0.38 ± 0.07
Heart 0.31 ± 0.05 0.16 ± 0.03 0.33 ± 0.07 0.35 ± 0.08
Lung 0.62 ± 0.09 0.33 ± 0.06 0.80 ± 0.07 0.87 ± 0.12
Spleen 0.73 ± 0.05 0.34 ± 0.05 1.73 ± 0.44 1.34 ± 0.21
Liver 1.02 ± 0.13 0.37 ± 0.20 1.86 ± 0.23 1.60 ± 0.27
Pancreas 0.21 ± 0.01 0.09 ± 0.07 0.23 ± 0.08 0.29 ± 0.05
Stomach 0.54 ± 0.13 0.12 ± 0.02 1.40 ± 0.34 1.50 ± 0.36
Intestine 0.31 ± 0.01 0.13 ± 0.01 1.83 ± 0.51 1.79 ± 0.30
Kidney 1.65 ± 0.12 0.87 ± 0.16 1.98 ± 0.51 2.24 ± 0.34
Muscle 0.18 ± 0.01 0.09 ± 0.01 0.49 ± 0.29 0.29 ± 0.04
Bone 0.36 ± 0.06 0.14 ± 0.04 0.45 ± 0.21 0.35 ± 0.05
Tumor 2.10 ± 0.09 0.29 ± 0.16 5.19 ± 1.45 3.47 ± 0.78
Tumor-to-blood 3.91 ± 0.43 27.67 ± 7.01 9.24 ± 1.12
Tumor-to-kidney 1.27 ± 0.04 2.64 ± 0.31 1.57 ± 0.14
Tumor-to-liver 2.08 ± 0.18 2.75 ± 0.31 2.25 ± 0.37
Tumor-to-muscle 11.69 ± 0.29 12.80 ± 5.25 12.37 ± 1.81
Fig. 1 Inhibition of [125I]I-echistatin binding to integrin αvß3 on U-87 MG cells by c(RGDfK) 2 (IC50 = 159.5 ±
1.3 nM) and natGa-NODIA-Me-c(RGDfK) [natGa]3 (IC50 = 205.1 ± 1.4 nM) (n = 2 in triplicate, mean ± SD)
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accumulation of radioactivity was attributed to the positive overall charge of the metal
complexes. In the present study, [68Ga]3 exhibited the lowest kidney uptake compared to
the previously described compounds [68Ga]Ga-NODAGA-c(RGDfK) and [68Ga]Ga-
DOTA-c(RGDfK). Obviously, the pharmacokinetics of [68Ga]3 are mainly determined by
the peptidic targeting vector. However, all three compounds make use of different
bifunctional chelators that produce 68Ga complexes of different shape, overall charge and
lipophilicity. In contrast to DOTA and NODAGA, the chelator NODIA-Me 1 does not
possess any charge compensating donor atoms and forms complexes with [68Ga]Ga3+ of
an overall charge of either 2+ or 3+, whether the remaining coordination site of the
gallium octahedron is occupied by a monodentate ligand such as hydroxide or chloride or
not. While we have been able to characterize the exchange of chloride vs. hydroxide for
the bioconjugate NODIA-Me-PSMA (Schmidtke et al. 2017), we neither observed such
an exchange in a more recent study with another PSMA-targeting conjugate (Läppchen
et al. 2018) nor in the present study. On the other hand, [68Ga]Ga-NODAGA-c(RGDfK)
and [68Ga]Ga-DOTA-c(RGDfK) give complexes that have an overall charge of 0 and − 1,
respectively (Dumont et al. 2011). Obviously, the differences of the metal chelates resulted
in different pharmacokinetic profiles of the tracers underlining the influence of the metal
binding moiety on the biological properties of the final radiopharmaceutical. A similar
trend as found for the kidneys was observed for the liver with [68Ga]3 exhibiting the
lowest liver uptake in this series. On the other hand, the blood activity of [68Ga]3 with 0.
54 ± 0.08 %IA g− 1 was comparable to that of [68Ga]Ga-DOTA-c(RGDfK) with 0.38 ± 0.07
%IA g− 1 and slightly higher than that of [68Ga]Ga-NODAGA-c(RGDfK) with 0.16 ± 0.03
%IA g− 1. Accumulation of [68Ga]3 at 1 h p.i. in all other organs was low (< 1 %IA g− 1).
Interestingly, [68Ga]3 exhibited lower uptake in the spleen, intestine, stomach and lung
compared to [68Ga]Ga-NODAGA-c(RGDfK) and [68Ga]Ga-DOTA-c(RGDfK). Despite the
lower tumor uptake, the tumor-to-tissue ratios of [68Ga]3 for the liver, kidneys and
muscle are comparable to those of [68Ga]Ga-NODAGA-c(RGDfK) and [68Ga]Ga-DOTA-
c(RGDfK) (Table 1).
The specificity of [68Ga]3 for integrin αvß3 was confirmed in blocking studies by co-
injection of an ~100fold excess c(RGDfK), which resulted in a significant reduction of
tracer uptake in all tissues (P values < 0.05 for all tissues). This is in accordance with the
literature where αvß3 imaging probes demonstrate low but blockable uptake in normal tis-
sues (Chen et al. 2004; Decristoforo et al. 2008; Dijkgraaf et al. 2011; Li et al. 2007; Wei et
al. 2009).
Small-animal PET imaging
In addition to the ex vivo biodistribution studies, the distribution profile of [68Ga]3 was
also assessed 1 h after administration by small-animal PET imaging. Corresponding
transverse and coronal maximum intensity projections of [68Ga]3 in αvß3 xenograft
bearing mice along with blocking studies are given Fig. 2. The results of the
biodistribution study were confirmed by PET imaging. The αvß3 positive U-87 MG tu-
mors as well as the liver and the kidneys were clearly visible on the PET images. The
tumor uptake of [68Ga]3 was determined to 2.48 ± 0.14 %IA g− 1. The differences in
blood and tissue activity versus tumor activity between [68Ga]3, [68Ga]Ga-NODAGA-
c(RGDfK) and [68Ga]Ga-DOTA-c(RGDfK) gave a tumor-to-background ratio of 6.76
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for [68Ga]3 that was lower than that of [68Ga]Ga-NODAGA-c(RGDfK) (11.97) but
about 2-fold higher than that of [68Ga]Ga-DOTA-c(RGDfK) (3.28) (Dumont et al.
2011). The specificity of [68Ga]3 was confirmed in blockade studies by co-injecting
c(RGDfK) shown in Fig. 2b, which resulted in a significant reduction of tumor accumu-
lation (0.67 ± 0.10 %IA g− 1) (P value < 0.0001) and reduced uptake in all other organs.
Conclusions
In this work, we successfully developed a 68Ga-labelled bioconjugate comprising our
novel chelator NODIA-Me for imaging the αvß3 integrin receptor. The final bioconju-
gate was readily obtained in a single reaction step by standard peptide chemistry in
good yields. The resulting bioconjugate was labelled with [68Ga]GaCl3 in a cGMP
compliant process in high yields and moderate specific activity. Introduction of the
novel metal chelate to the peptide c(RGDfK) had only a minimal impact on receptor
binding. U-87 MG tumors overexpressing the αvß3 integrin receptor were specifically
delineated in ex vivo biodistribution and small-animal PET imaging studies by the cor-
responding 68Ga-labelled bioconjugate. Uptake of the novel tracer in non-target tissues
was low providing acceptable tumor-to-background ratios. Even though tumor uptake
and tumor-to-background ratios were lower compared to [68Ga]Ga-NODAGA-
Fig. 2 a Representative coronal (top) and transverse (bottom) maximum intensity projections (MIPs) of
[68Ga]3 at 1 h p.i. in U-87 MG tumor bearing mice. b Blocking studies confirmed the specificity of [68Ga]3
for αvß3 expression. White arrows indicate the tumors
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c(RGDfK), the low uptake in non-target tissues indicates kinetically stable complexation
of gallium-68 in the bifunctional chelator NODIA-Me. Altogether, our results demon-
strate that our novel chelating system is an interesting alternative to existing bifunc-
tional chelators such as DOTA and NODAGA for 68Ga-based radiopharmaceuticals.
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